Skip to content

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome

Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome - SECRETO

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON43346
Enrollment
60
Registered
2017-07-18
Start date
2016-09-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infarction ischemic stroke

Interventions

Cryptogenic
Stroke
Young

Sponsors

Helsinki University Central Hospital
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Ischemic stroke Age 18 - 49 years Hospitalized due to first-ever imaging postive ischemic stroke without cause found after complete and timely minimum diagnostic testing

Exclusion criteria

Exclusion criteria: Baseline mandatory minimum tests not obtained in the first week following stroke onset, including: a. Brain MRI b. Routine blood tests, including complete blood count with differential, CRP, fasting glucose, creatinine, aPTT, INR, total cholesterol, LDL-cholesterol, HDL-cholesterol, HbA1C, and hemoglobin electrophoresis in individuals of African origin Other baseline mandatory minimum tests not obtained within the first two weeks following stroke onset, including: a. Imaging of cervicocephalic arteries by CTA, MRA, or DSA b. Transesophageal (highly recommended) and/or transthoracic echocardiography (N.B. Early screening of venous thrombosis in the lower extremities is highly recommended in patients with established right-to-left shunt) c. 24-hour Holter monitoring (or continuous in-hospital ECG monitoring for at least 24 h) d. Screening for thrombophilia, including anticardiolipin antibodies, lupus anticoagulant, anti-β2- glycoprotein antibodies, factor V mutation (or aPC resistency ruled out), factor II mutation, homocysteine, antithrombin III, protein C, and protein S. It is highly recommended to retest any abnormal finding >12 weeks from the initial testing or >4 weeks after cessation of anticoagulation at any later time point.

Design outcomes

Primary

MeasureTime frame
Etiology (TOAST) Mortality New vascular events

Secondary

MeasureTime frame
Risk factors Other outcome (hypertension, diabetes)

Countries

Finland, Norway, Portugal, Turkey

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)